BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
December 18, 2024 09:00 ET
|
BioAge Labs, Inc.
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to...
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
December 06, 2024 16:35 ET
|
BioAge Labs, Inc.
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated...
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
December 05, 2024 16:30 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs to Present at Upcoming Investor Conferences
November 21, 2024 16:30 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 07, 2024 16:30 ET
|
BioAge Labs, Inc.
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents...
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
November 04, 2024 09:00 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...
BioAge Labs to Present at Jefferies London Healthcare Conference
October 24, 2024 09:00 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases...
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
October 01, 2024 16:30 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
September 25, 2024 20:00 ET
|
BioAge Labs, Inc.
RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
BioAge Raises $90M to Treat Aging and Age-related Diseases
December 03, 2020 08:00 ET
|
BioAge Labs, Inc.
Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging Company announces Chief Medical Officer as it...